Lesinurad (Zurampic) for Gout-Associated Hyperuricemia
Lesinurad (Zurampic) for Gout-Associated Hyperuricemia
November 21, 2016 (Issue: 1508)
The FDA has approved lesinurad (Zurampic –
Ironwood), a uric acid transporter 1 (URAT1)
inhibitor, for adjunctive treatment of gout-associated
hyperuricemia in patients whose serum uric acid
levels fail to reach goal with xanthine...more
- D Khanna et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64:1431.
- P Richette et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2016 July 25 (epub).
- PG Shekelle et al. Management of gout: a systematic review in support of an American College of Physicians clinical practice guideline. Ann Intern Med 2016 November 1 (epub).
- Drugs for gout. Med Lett Drugs Ther 2014; 56:22.
- JN Miner et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther 2016; 18:214.
- KG Saag et al. Lesinurad combined with allopurinol: randomized, double-blind, placebo-controlled study in gout subjects with inadequate response to standard of care allopurinol (a US-based study). Arthritis Rheumatol 2016 August 26 (epub).
- T Bardin et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with allopurinol: results from a phase III study in gout patients having an inadequate response to standard of care (CLEAR 2). Ann Rheum Dis 2015; 74 (Suppl 2):545.
- N Dalbeth et al. Lesinurad, a novel selective uric acid reabsorption inhibitor, in combination with febuxostat, in patients with tophaceous gout: the CRYSTAL phase III clinical trial. Ann Rheum Dis 2015; 74 (Suppl 2):778.
- AK Tausche et al. Lesinurad monotherapy in gout patients intolerant to xanthine oxidase inhibitors (LIGHT): a randomized, double-blind, placebo-controlled, 6-month phase III clinical trial. Ann Rheum Dis 2015; 74 (Suppl 2):769.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2016 Aug 2 (epub). Available at: secure. medicalletter.org/downloads/CYP_PGP_Tables.pdf. Accessed November 10, 2016.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Lesinurad (Zurampic) for Gout-Associated Hyperuricemia
Article code: 1508b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
